Longidaza

ApprovedSmall molecule

NNPO Petrovax

Longidaza is one of 38 small molecule programs targeting Bacterial Vaginosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial VaginosisActive, not recruiting

COVID-19Active, not recruiting

Bacterial VaginosisApproved

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Longidaza

NNPO Petrovax

Approved

1 2

Spikevax

Moderna

Preclinical

21 3

Stivarga

Bayer

Preclinical

1 4

Aimovig

Amgen

Preclinical

1 5

Activella

Rayaldee

1 7

Achromycin V

WWyeth-Lederle Vaccines

Statins

1 9

Calcium

Olokizumab

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bacterial Vaginosis1 trial

Optimization of Bacterial Vaginosis Treatment in Women of Reproductive Age

Recruiting·II.M. Sechenov First Moscow State Medical University·Phase 4·NCT06458543·100 enrolled

COVID-191 trial

Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19

Completed·NNPO Petrovax·Phase 3·NCT06383819·392 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Longidaza. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Longidaza compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Longidaza. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NPO Petrovax company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNPO Petrovax

Longidaza

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bacterial Vaginosis1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News